目的:探讨溶质载体家族22成员14(SLC22A14)和精子相关抗原6(SPAG6),在特发性弱精子症患者精子中的表达情况。方法:收集精子库合格捐精者(正常对照组)和特发性弱精子症患者(弱精子症组)各50例精子样本,采用非连续密度梯度离心纯化精子,...目的:探讨溶质载体家族22成员14(SLC22A14)和精子相关抗原6(SPAG6),在特发性弱精子症患者精子中的表达情况。方法:收集精子库合格捐精者(正常对照组)和特发性弱精子症患者(弱精子症组)各50例精子样本,采用非连续密度梯度离心纯化精子,分别用RT-PCR和Western印迹检测SLC22A14、SPAG6 mRNA及蛋白的表达。结果:RT-PCR检测结果显示,弱精子症组的SLC22A14、SPAG6 mRNA表达均显著低于正常对照组(SLC22A14:0.53±0.10 vs 0.77±0.08,t=12.834,P<0.01;SPAG6:0.52±0.10 vs 0.77±0.06,t=13.755,P<0.01),Western印迹检测结果显示,弱精子症组的SLC22A14和SPAG6蛋白表达量同样均显著低于正常对照组,分别为(SLC22A14:0.55±0.10 vs 0.80±0.09,t=12.884,P<0.01;SPAG6:0.56±0.09 vs 0.78±0.09,t=12.257,P<0.01)。结论:在特发性弱精子症患者中SLC22A14和SPAG6表达降低可能是导致弱精子症的重要原因之一。展开更多
The main treatment strategy for glucose-6-phosphate dehydrogenase (G6PD) deficiency is averting the use of oxidative precipitants like drugs or foods that trigger haemolysis. However, subjects could experience acute c...The main treatment strategy for glucose-6-phosphate dehydrogenase (G6PD) deficiency is averting the use of oxidative precipitants like drugs or foods that trigger haemolysis. However, subjects could experience acute crisis in a comorbidity state of diabetes, hypertension or infection. In addition, the condition could in turn predispose carriers to these chronic diseases. Aim of the study was to evaluate the frequency of haemolytic crisis in carriers with attendant chronic diseases, and also assess awareness and knowledge of aggravated reactions from these conditions. 282 subjects consented and participated in the study. A cross-sectional semi-structured interview questionnaire conducted from May to August 2013 was adopted. Questions focused on demographics, awareness and when disease was diagnosed, type and frequency of crisis, family history, screening and presence of other diseases and awareness of trigger from these conditions. A total of 69.9% were G6PD deficiency gene carriers and mostly fell within the age group of 31 - 40 (43.6%). 75.6% of the carriers were not aware that other disease conditions could exacerbate crisis. Non-drug related crisis was 85.3% compared with 14.7 drug related reactions. Out of the 69.9% carriers, 17.3% are diabetics, 18.3% of them are hypertensive and 25.9% are with bleeding disorders. Also, 29.1% had frequent episodes with bacterial infection. Symptoms experienced that were not drug related included, 44.8% attacks of pallor, 25.3% jaundice, 28.5% with shortness of breath, while 21.7% had dark urine frequently. No routine screening for other diseased conditions was carried out for these subjects despite experiencing frequent crisis that were not drug related. Carriers with other diseased conditions experienced more non-drug related crisis and were not aware of it.展开更多
Lead-free double perovskite Cs_(2)AgBiBr_(6) has gained increasing attention recently.However,the power conversion efficiency(PCE)of Cs_(2)AgBiBr_(6) perovskite solar cells(PSCs)is still low compared with their lead-b...Lead-free double perovskite Cs_(2)AgBiBr_(6) has gained increasing attention recently.However,the power conversion efficiency(PCE)of Cs_(2)AgBiBr_(6) perovskite solar cells(PSCs)is still low compared with their lead-based counterparts.Here,by using photoluminescence(PL),time-resolved photoluminescence(TRPL),and ultrafast transient absorption(TA)measurements,the unbalance between the electron and hole in diffusion and transfer,which limits the performance of the Cs_(2)AgBiBr_(6) PSCs,was further revealed.Considering this issue,a strategy of using the mesoporous TiO_(2) electron transport layer(ETL)to construct a bulk heterojunction in Cs_(2)AgBiBr_(6) PSCs was proposed.Consequently,the PCE had improved by over 24%comparing with that only used compact TiO_(2) ETL.Moreover,based on mesoporous TiO_(2),the unencapsulated Cs_(2)AgBiBr_(6) PSCs maintained 90%of their initial performance after approximately 1200 h of storage in a desiccator(humidity~30%).This work gives further understanding of Cs_(2)AgBiBr_(6) perovskite and demonstrates that a proper design of balancing the electron and hole diffusion can improve device performance.展开更多
文摘目的:探讨溶质载体家族22成员14(SLC22A14)和精子相关抗原6(SPAG6),在特发性弱精子症患者精子中的表达情况。方法:收集精子库合格捐精者(正常对照组)和特发性弱精子症患者(弱精子症组)各50例精子样本,采用非连续密度梯度离心纯化精子,分别用RT-PCR和Western印迹检测SLC22A14、SPAG6 mRNA及蛋白的表达。结果:RT-PCR检测结果显示,弱精子症组的SLC22A14、SPAG6 mRNA表达均显著低于正常对照组(SLC22A14:0.53±0.10 vs 0.77±0.08,t=12.834,P<0.01;SPAG6:0.52±0.10 vs 0.77±0.06,t=13.755,P<0.01),Western印迹检测结果显示,弱精子症组的SLC22A14和SPAG6蛋白表达量同样均显著低于正常对照组,分别为(SLC22A14:0.55±0.10 vs 0.80±0.09,t=12.884,P<0.01;SPAG6:0.56±0.09 vs 0.78±0.09,t=12.257,P<0.01)。结论:在特发性弱精子症患者中SLC22A14和SPAG6表达降低可能是导致弱精子症的重要原因之一。
文摘The main treatment strategy for glucose-6-phosphate dehydrogenase (G6PD) deficiency is averting the use of oxidative precipitants like drugs or foods that trigger haemolysis. However, subjects could experience acute crisis in a comorbidity state of diabetes, hypertension or infection. In addition, the condition could in turn predispose carriers to these chronic diseases. Aim of the study was to evaluate the frequency of haemolytic crisis in carriers with attendant chronic diseases, and also assess awareness and knowledge of aggravated reactions from these conditions. 282 subjects consented and participated in the study. A cross-sectional semi-structured interview questionnaire conducted from May to August 2013 was adopted. Questions focused on demographics, awareness and when disease was diagnosed, type and frequency of crisis, family history, screening and presence of other diseases and awareness of trigger from these conditions. A total of 69.9% were G6PD deficiency gene carriers and mostly fell within the age group of 31 - 40 (43.6%). 75.6% of the carriers were not aware that other disease conditions could exacerbate crisis. Non-drug related crisis was 85.3% compared with 14.7 drug related reactions. Out of the 69.9% carriers, 17.3% are diabetics, 18.3% of them are hypertensive and 25.9% are with bleeding disorders. Also, 29.1% had frequent episodes with bacterial infection. Symptoms experienced that were not drug related included, 44.8% attacks of pallor, 25.3% jaundice, 28.5% with shortness of breath, while 21.7% had dark urine frequently. No routine screening for other diseased conditions was carried out for these subjects despite experiencing frequent crisis that were not drug related. Carriers with other diseased conditions experienced more non-drug related crisis and were not aware of it.
基金financial support from Macao Science and Technology Development Fund,China(FDCT-0044/2020/A1,FDCT-091/2017/A2,FDCT-014/2017/AMJ)University of Macao Research Grant,China(MYRG2018-00148-IAPME,MYRG2018-00142-IAPME)from University of Macao+2 种基金the Natural Science Foundation of China,China(91733302,61935017)Guangdong-Hong Kong-Macao Joint Laboratory of Optoelectronic and Magnetic Functional Materials(2019B121205002)Natural Science Foundation of Guangdong Province,China(2019A1515012186).
文摘Lead-free double perovskite Cs_(2)AgBiBr_(6) has gained increasing attention recently.However,the power conversion efficiency(PCE)of Cs_(2)AgBiBr_(6) perovskite solar cells(PSCs)is still low compared with their lead-based counterparts.Here,by using photoluminescence(PL),time-resolved photoluminescence(TRPL),and ultrafast transient absorption(TA)measurements,the unbalance between the electron and hole in diffusion and transfer,which limits the performance of the Cs_(2)AgBiBr_(6) PSCs,was further revealed.Considering this issue,a strategy of using the mesoporous TiO_(2) electron transport layer(ETL)to construct a bulk heterojunction in Cs_(2)AgBiBr_(6) PSCs was proposed.Consequently,the PCE had improved by over 24%comparing with that only used compact TiO_(2) ETL.Moreover,based on mesoporous TiO_(2),the unencapsulated Cs_(2)AgBiBr_(6) PSCs maintained 90%of their initial performance after approximately 1200 h of storage in a desiccator(humidity~30%).This work gives further understanding of Cs_(2)AgBiBr_(6) perovskite and demonstrates that a proper design of balancing the electron and hole diffusion can improve device performance.
